TAPI-1
Appearance
![]() | |
Names | |
---|---|
Systematic IUPAC name
(2R)-N1-[(2S)-1-({(2S)-1-[(2-Aminoethyl)amino]-1-oxopropan-2-yl}amino)-3-(naphthalen-2-yl)-1-oxopropan-2-yl]-N4-hydroxy-2-(2-methylpropyl)butanediamide | |
Other names
N-{(2R)-2-[2-(Hydroxyamino)-2-oxoethyl]-4-methylpentanoyl}-3-(2-naphthyl)-L-alanyl-N-(2-aminoethyl)-L-alaninamide
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C26H37N5O5 | |
Molar mass | 499.612 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
TAPI-1 ( TNF-alpha protease inhibitor I) is a structural analog of TAPI-0 with similar but more stable validness[clarification needed] in vitro for the matrix metalloproteinases (MMPs) and TNF- alpha converting enzyme[1] which blocks shedding of several cell surface proteins such as IL-6 and p60 TNF receptor.[2]
References[edit]
- ^ Müllberg J rt al; Durie; Otten-Evans; Alderson; Rose-John; Cosman; Black; Mohler (Dec 1, 1995). "A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor". J Immunol. 155 (11): 5198–5205. doi:10.4049/jimmunol.155.11.5198. PMID 7594530.
- ^ "TAPI-1 biological activity". selleckchemicals.